222 related articles for article (PubMed ID: 28756584)
1. Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis.
Elliott TM; Whiteman DC; Olsen CM; Gordon LG
Appl Health Econ Health Policy; 2017 Dec; 15(6):805-816. PubMed ID: 28756584
[TBL] [Abstract][Full Text] [Related]
2. Modelling the healthcare costs of skin cancer in South Africa.
Gordon LG; Elliott TM; Wright CY; Deghaye N; Visser W
BMC Health Serv Res; 2016 Apr; 16():113. PubMed ID: 27039098
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin Cancer Targeting Men Older Than 50 Years.
Gordon LG; Brynes J; Baade PD; Neale RE; Whiteman DC; Youl PH; Aitken JF; Janda M
Value Health; 2017 Apr; 20(4):593-601. PubMed ID: 28408001
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.
Watts CG; Cust AE; Menzies SW; Mann GJ; Morton RL
J Clin Oncol; 2017 Jan; 35(1):63-71. PubMed ID: 28034073
[TBL] [Abstract][Full Text] [Related]
5. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
Alexandrescu DT
Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
[TBL] [Abstract][Full Text] [Related]
6. A National Budget Impact Analysis of a Specialised Surveillance Programme for Individuals at Very High Risk of Melanoma in Australia.
Watts CG; Wortley S; Norris S; Menzies SW; Guitera P; Askie L; Mann GJ; Morton RL; Cust AE
Appl Health Econ Health Policy; 2018 Apr; 16(2):235-242. PubMed ID: 29305821
[TBL] [Abstract][Full Text] [Related]
7. An estimate of the annual direct cost of treating cutaneous melanoma.
Tsao H; Rogers GS; Sober AJ
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):669-80. PubMed ID: 9591809
[TBL] [Abstract][Full Text] [Related]
8. Estimated Healthcare Costs of Melanoma and Keratinocyte Skin Cancers in Australia and Aotearoa New Zealand in 2021.
Gordon LG; Leung W; Johns R; McNoe B; Lindsay D; Merollini KMD; Elliott TM; Neale RE; Olsen CM; Pandeya N; Whiteman DC
Int J Environ Res Public Health; 2022 Mar; 19(6):. PubMed ID: 35328865
[TBL] [Abstract][Full Text] [Related]
9. The economic burden of melanoma in France: assessing healthcare use in a hospital setting.
Chevalier J; Bonastre J; Avril MF
Melanoma Res; 2008 Feb; 18(1):40-6. PubMed ID: 18227707
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of reduced follow-up in malignant melanoma.
Hengge UR; Wallerand A; Stutzki A; Kockel N
J Dtsch Dermatol Ges; 2007 Oct; 5(10):898-907. PubMed ID: 17910672
[TBL] [Abstract][Full Text] [Related]
11. Lifetime cost-effectiveness of skin cancer prevention through promotion of daily sunscreen use.
Hirst NG; Gordon LG; Scuffham PA; Green AC
Value Health; 2012; 15(2):261-8. PubMed ID: 22433757
[TBL] [Abstract][Full Text] [Related]
12. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review.
Gordon LG; Rowell D
Eur J Cancer Prev; 2015 Mar; 24(2):141-9. PubMed ID: 25089375
[TBL] [Abstract][Full Text] [Related]
13. Cost of Cutaneous Melanoma by Tumor Stage: A Descriptive Analysis.
Serra-Arbeloa P; Rabines-Juárez ÁO; Álvarez-Ruiz MS; Guillén-Grima F
Actas Dermosifiliogr; 2017 Apr; 108(3):229-236. PubMed ID: 27887672
[TBL] [Abstract][Full Text] [Related]
14. An estimate of the cost of treating melanoma disease in the state of Sao Paulo - Brazil.
Souza RJ; Mattedi AP; Rezende ML; Corrêa Mde P; Duarte EM
An Bras Dermatol; 2009 Jul; 84(3):237-43. PubMed ID: 19668936
[TBL] [Abstract][Full Text] [Related]
15. Confirming the timing of phase-based costing in oncology studies: a case example in advanced melanoma.
Atkins M; Coutinho AD; Nunna S; Gupte-Singh K; Eaddy M
J Med Econ; 2018 Feb; 21(2):212-217. PubMed ID: 29022427
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy.
Tromme I; Legrand C; Devleesschauwer B; Leiter U; Suciu S; Eggermont A; Sacré L; Baurain JF; Thomas L; Beutels P; Speybroeck N
Eur J Cancer; 2016 Nov; 67():38-45. PubMed ID: 27592070
[TBL] [Abstract][Full Text] [Related]
17. Non-melanoma skin cancer in Australia.
Fransen M; Karahalios A; Sharma N; English DR; Giles GG; Sinclair RD
Med J Aust; 2012 Nov; 197(10):565-8. PubMed ID: 23163687
[TBL] [Abstract][Full Text] [Related]
18. An estimate of the cost of treating non-melanoma skin cancer in the state of São Paulo, Brazil.
Souza RJ; Mattedi AP; Corrêa MP; Rezende ML; Ferreira AC
An Bras Dermatol; 2011; 86(4):657-62. PubMed ID: 21987129
[TBL] [Abstract][Full Text] [Related]
19. Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines.
Buja A; Sartor G; Scioni M; Vecchiato A; Bolzan M; Rebba V; Sileni VC; Palozzo AC; Montesco M; Del Fiore P; Baldo V; Rossi CR
Acta Derm Venereol; 2018 Feb; 98(2):218-224. PubMed ID: 29110018
[TBL] [Abstract][Full Text] [Related]
20. Economic Costs Avoided by Diagnosing Melanoma Six Months Earlier Justify >100 Benign Biopsies.
Aires DJ; Wick J; Shaath TS; Rajpara AN; Patel V; Badawi AH; Li C; Fraga GR; Doolittle G; Liu DY
J Drugs Dermatol; 2016 May; 15(5):527-32. PubMed ID: 27168261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
